What is the mechanism of action of CJC-1295 + Ipamorelin Blend?

CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The two pathways converge on the same somatotroph but use independent receptors, producing a multiplicative rather than additive GH pulse. Ipamorelin's selectivity avoids the cortisol/prolactin elevation seen with GHRP-6 and GHRP-2. For anabolic and recovery applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The body composition / training interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What is the standard dosing protocol for CJC-1295 + Ipamorelin Blend?

Conventional CJC-1295 + Ipamorelin Blend dosing is 100 mcg CJC + 200 mcg ipamorelin 1-3x daily subq via subq. For anabolic and recovery use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What does CJC-1295 + Ipamorelin Blend stack well with?

For body composition / training protocols, CJC-1295 + Ipamorelin Blend pairs with compounds on complementary pathways: IGF-1 LR3, TB-500, BPC-157. These pairings are selected because they engage independent receptor systems from CJC-1295 + Ipamorelin Blend's primary mechanism (CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor), producing additive or synergistic effects rather than receptor competition.

How long until I see results from CJC-1295 + Ipamorelin Blend?

Acute effects from CJC-1295 + Ipamorelin Blend appear within the first week for downstream physiological adaptation. anabolic and recovery endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What is the regulatory status of CJC-1295 + Ipamorelin Blend?

CJC-1295 + Ipamorelin Blend regulatory status: Unapproved in the United States; WADA status both components banned (s2); research level off-label clinical use; mechanistic studies. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For anabolic and recovery use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

Home/ Compounds/ CJC-1295 + Ipamorelin Blend

CJC-1295 + Ipamorelin Blend

Body Composition

Athletes and performance coaches evaluating CJC-1295 + Ipamorelin Blend for body composition focus on three measurable endpoints: lean mass, recovery capacity, and the rate of return to training intensity between sessions. CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor The two pathways converge on the same somatotroph but use independent receptors, producing a multiplicative rather than additive GH pulse. Ipamorelin's selectivity avoids the cortisol/prolactin elevation seen with GHRP-6 and GHRP-2.. The 100 mcg CJC + 200 mcg ipamorelin 1-3x daily subq protocol over the standard 8-12 week cycle, paired with training stimulus and nutritional adequacy, is where the body-composition response is generated.

Body Composition / Training Applications

RecoveryCardiovascular ConditioningLean MassWorkout RecoveryBody Recomposition

Key Takeaways

Body composition lens: response to CJC-1295 + Ipamorelin Blend is proportional to training stimulus and nutritional adequacy.
Mechanism: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor.
Body composition dose: 100 mcg CJC + 200 mcg ipamorelin 1-3x daily subq via subq; effects visible at week 4-8 with adequate training and protein.
Cycle structure: 8-12 weeks on, 4 weeks off; training-day or daily dosing depending on half-life.
Performance stack partners: IGF-1 LR3, TB-500, BPC-157.

Body Composition / Training Mechanism

For trained users, CJC-1295 + Ipamorelin Blend's body composition response is generated at the intersection of compound pharmacology, training stimulus, and nutritional input. CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The two pathways converge on the same somatotroph but use independent receptors, producing a multiplicative rather than additive GH pulse. Ipamorelin's selectivity avoids the cortisol/prolactin elevation seen with GHRP-6 and GHRP-2. The mechanism informs which training and nutrition pattern maximises the response; the subsections below work through this for the four dimensions tracked in body composition protocols.

Training-day versus rest-day dosing

Many peptides in this category respond better to training-day-only versus rest-day-included dosing. CJC-1295 + Ipamorelin Blend with a Mixed half-life of Mixed is short-lived enough that timing relative to training sessions matters. The practical dosing schedule reflects this.

Hyperplasia and structural adaptation

Where CJC-1295 + Ipamorelin Blend demonstrates effects on fibre count rather than fibre size — hyperplasia rather than hypertrophy — the structural adaptation matters more than the acute anabolic signal. Most peptides in this category contribute to the hypertrophic rather than hyperplastic adaptation, with the magnitude depending on training stimulus.

Recovery window and training frequency

The most reliably reported effect of CJC-1295 + Ipamorelin Blend in athlete populations is on the recovery window between sessions. Faster connective tissue recovery, better sleep quality, and reduced systemic inflammation translate into more high-quality training days per cycle. This is the practical mechanism by which body composition shifts for most users — not via dramatic acute anabolic effect but via more accumulated quality training.

Body Composition / Training Applications

Lean Mass

For lean mass, CJC-1295 + Ipamorelin Blend integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Endurance

The body composition community converges on CJC-1295 + Ipamorelin Blend for endurance with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Body Recomposition

Body Recomposition responds to CJC-1295 + Ipamorelin Blend with effect sizes proportional to training stimulus and nutritional adequacy. Users running aggressive caloric deficits see reduced response; users in surplus with adequate protein see proportionally larger response. Programming the inputs is half the protocol.

Workout Recovery

For workout recovery, CJC-1295 + Ipamorelin Blend integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	100 mcg CJC + 200 mcg ipamorelin	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	60 mcg CJC + 200 mcg ipamorelin	4–6 weeks initial cycle
Body Composition focus	SubQ	100 mcg CJC + 200 mcg ipamorelin	1-3x daily SubQ
Maintenance phase	SubQ	70 mcg CJC + 200 mcg ipamorelin	Ongoing with periodic pauses

Dose timing for CJC-1295 + Ipamorelin Blend is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

CJC-1295 + Ipamorelin Blend stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from performance coaches and athletes.

CJC-1295 + Ipamorelin Blend + IGF-1 LR3: Binds the IGF-1 receptor with full agonist activity. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in body composition / training protocols.
CJC-1295 + Ipamorelin Blend + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in body composition / training protocols.
CJC-1295 + Ipamorelin Blend + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in body composition / training protocols.
CJC-1295 + Ipamorelin Blend + Tesamorelin + Ipamorelin Blend: Tesamorelin engages the GHRH receptor; ipamorelin engages the GHSR. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in body composition / training protocols.

Safety & Regulatory Status

WADA: Both components banned (S2) FDA: Unapproved Research: Off-label clinical use; mechanistic studies

Lowest-side-effect profile of GH-releasing stacks. Site reactions and mild flushing possible.

Lens-specific safety considerations for body composition / training use of CJC-1295 + Ipamorelin Blend: Lowest-side-effect profile of GH-releasing stacks. Site reactions and mild flushing possible. Additional body composition / training monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Ipamorelin selective GH secretagogue

PMID 9849822

CJC-1295 + Ipamorelin Blend vs Related Peptides

Compound	Profile	Onset	Best For
CJC-1295 + Ipamorelin Blend	GHRH + GHRP combination	Mixed	Body Composition
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	A modified IGF-1 with a 13-amino-acid N-terminal extension and Arg substitution that resists IGFBP binding — extending half-life from 10 minutes to roughly a day
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Can I use CJC-1295 + Ipamorelin Blend alongside creatine, protein, and standard supplements?

Yes — peptide protocols are fully compatible with the standard supplement stack. Creatine, protein powder, beta-alanine, citrulline, and the like operate on entirely separate mechanisms and are additive. Pre-workout stimulants and high-caffeine intake are also compatible.

Will CJC-1295 + Ipamorelin Blend affect my training performance?

Most commonly via faster recovery between sessions, which permits higher training frequency and intensity. Acute performance-enhancing effects in a single session are not the typical profile. Users typically need to upregulate nutrition and adjust programming to take advantage of the increased recovery capacity.

How does CJC-1295 + Ipamorelin Blend compare to AAS for body composition?

Peptide therapeutics including CJC-1295 + Ipamorelin Blend produce more modest body composition shifts than anabolic-androgenic steroids and operate on different mechanisms with substantially different side-effect profiles. The compound is most-appropriate for users prioritising long-term sustainability and clean blood work over maximum acute mass.

Should I cycle CJC-1295 + Ipamorelin Blend?

Standard cycle structure for body composition use is 8–12 weeks on, 4 weeks off. Continuous indefinite use is not advised for most compounds in this class; the off-period preserves dose response and reduces cumulative downregulation. Cycle stacking with complementary peptides is common in advanced protocols.

What is CJC-1295 + Ipamorelin Blend?

CJC-1295 + Ipamorelin Blend (also known as CJC/Ipa / GH-Releasing Stack) is a small ghrh + ghrp combination with a molecular weight of Variable and a plasma half-life of Mixed. CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The two pathways converge on the same somatotroph but use independent receptors, producing a multiplicative rather than additive GH pulse. Ipamorelin's selectivity avoids the cortisol/prolactin elevation seen with GHRP-6 and GHRP-2. The compound is studied primarily in the body composition / training domain for the applications outlined above.

How does CJC-1295 + Ipamorelin Blend's half-life affect dosing?

CJC-1295 + Ipamorelin Blend has a plasma half-life of Mixed, which is moderate, supporting once-daily dosing in most protocols. The receptor occupancy curve under 1-3x daily subq dosing at 100 mcg CJC + 200 mcg ipamorelin per dose explains the typical onset timeline for anabolic and recovery endpoints.

Clinical Protocol

Start a CJC-1295 + Ipamorelin Blend Protocol

Alukard provides physician-supervised body composition protocols with GMP-certified CJC-1295 + Ipamorelin Blend and GMP-certified compounds and training-aware dosing guidance.

Get Protocol

Quick Facts

Molecular weight: Variable
Half-life: Mixed
WADA: Both components banned (S2)
FDA: Unapproved
Research: Off-label clinical use; mechanistic studies

Stack Partners

IGF-1 LR3

TB-500

BPC-157

Tesamorelin + Ipamorelin Blend

Research Note

All body composition / training applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for CJC-1295 + Ipamorelin Blend unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised body composition protocols

Start Your Body Composition / Training Protocol for CJC-1295 + Ipamorelin Blend

Alukard provides physician-supervised body composition protocols with GMP-certified compounds and training-aware dosing guidance.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised